EMERGENT BIOSOLUTIONS INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
EMERGENT BIOSOLUTIONS INC. (EBS) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $43.20 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2019-11-07
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-09-30 was $43.20M, a 106.70% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-06-30 was -$9.50M, a 118.96% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-03-31 was -$26.00M.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2018-12-31 was -$3.40M, a 110.03% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2018 was $62.70M, a 24.09% decline from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2017 was $82.60M, a 32.16% increase from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2016 was $62.50M, a 31.63% decline from fiscal 2015.
- EMERGENT BIOSOLUTIONS INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2015 was $91.42M, a 68.46% increase from fiscal 2014.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-09-30 | $43.20M 10-Q · filed 2019-11-07 | $33.70M derived: sum of 2 quarters · filed 2019-11-07 | $7.60M 10-Q · filed 2019-11-07 | $4.30M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2019-06-30 | -$9.50M 10-Q · filed 2019-08-02 | -$35.60M 10-Q · filed 2019-08-02 | -$38.90M derived: sum of 3 quarters · filed 2019-08-02 | -$18.00M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2019-03-31 | -$26.00M 10-Q · filed 2019-05-08 | -$29.40M derived: sum of 2 quarters · filed 2019-05-08 | -$8.50M derived: sum of 3 quarters · filed 2019-11-07 | $41.60M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-12-31 | -$3.40M 10-K · filed 2019-02-22 | $17.50M derived: sum of 2 quarters · filed 2019-11-07 | $67.60M derived: sum of 3 quarters · filed 2019-11-07 | $62.70M 10-K · filed 2019-02-22 | ||||
| 2018-09-30 | $20.90M 10-Q · filed 2019-11-07 | $20.95M 10-Q · filed 2018-11-02 | $71.00M derived: sum of 2 quarters · filed 2019-11-07 | $66.20M 10-Q · filed 2019-11-07 | $66.18M 10-Q · filed 2018-11-02 | $100.00M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $50.10M 10-Q · filed 2019-08-02 | $50.14M 10-Q · filed 2018-08-03 | $45.20M 10-Q · filed 2019-08-02 | $45.24M 10-Q · filed 2018-08-03 | $79.10M derived: sum of 3 quarters · filed 2019-08-02 | $112.70M derived: sum of 4 quarters · filed 2019-08-02 | ||
| 2018-03-31 | -$4.90M 10-Q · filed 2019-05-08 | -$4.91M 10-Q · filed 2018-05-04 | $29.00M derived: sum of 2 quarters · filed 2019-05-08 | $62.60M derived: sum of 3 quarters · filed 2019-05-08 | $67.20M derived: sum of 4 quarters · filed 2019-05-08 | |||
| 2017-12-31 | $33.90M 10-K · filed 2019-02-22 | $33.94M 10-K · filed 2018-02-23 | $67.50M derived: sum of 2 quarters · filed 2019-02-22 | $72.10M derived: sum of 3 quarters · filed 2019-02-22 | $82.60M 10-K · filed 2019-02-22 | $82.59M 10-K · filed 2018-02-23 | ||
| 2017-09-30 | $33.60M 10-K · filed 2019-02-22 | $33.55M 10-Q · filed 2017-11-03 | $38.20M derived: sum of 2 quarters · filed 2019-02-22 | $48.65M 10-Q · filed 2018-11-02 | $80.99M derived: sum of 4 quarters · filed 2019-02-22 | |||
| 2017-06-30 | $4.60M 10-K · filed 2019-02-22 | $4.62M 10-Q · filed 2017-08-04 | $15.10M 10-Q · filed 2018-08-03 | $47.39M derived: sum of 3 quarters · filed 2019-02-22 | $67.78M derived: sum of 4 quarters · filed 2019-02-22 | |||
| 2017-03-31 | $10.50M 10-K · filed 2019-02-22 | $10.48M 10-Q · filed 2017-05-05 | $42.79M derived: sum of 2 quarters · filed 2019-02-22 | $63.18M derived: sum of 3 quarters · filed 2019-02-22 | $61.13M derived: sum of 4 quarters · filed 2019-02-22 | |||
| 2016-12-31 | $32.29M 10-K · filed 2018-02-23 | $52.68M derived: sum of 2 quarters · filed 2018-02-23 | $50.63M derived: sum of 3 quarters · filed 2018-02-23 | $62.50M 10-K · filed 2019-02-22 | $62.52M 10-K · filed 2017-02-28 | |||
| 2016-09-30 | $20.39M 10-K · filed 2018-02-23 | $18.35M derived: sum of 2 quarters · filed 2018-02-23 | $30.24M 10-Q · filed 2017-11-03 | $72.73M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-06-30 | -$2.04M 10-K · filed 2018-02-23 | $9.85M 10-Q · filed 2017-08-04 | $52.34M derived: sum of 3 quarters · filed 2018-02-23 | $94.43M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-03-31 | $11.89M 10-K · filed 2018-02-23 | $54.38M derived: sum of 2 quarters · filed 2018-02-23 | $96.47M derived: sum of 3 quarters · filed 2018-02-23 | $119.03M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2015-12-31 | $42.49M 10-K · filed 2017-02-28 | $84.58M derived: sum of 2 quarters · filed 2017-02-28 | $107.14M derived: sum of 3 quarters · filed 2017-02-28 | $91.42M 10-K · filed 2018-02-23 | ||||
| 2015-09-30 | $42.09M 10-K · filed 2017-02-28 | $64.65M derived: sum of 2 quarters · filed 2017-02-28 | $48.92M 10-Q · filed 2016-11-09 | |||||
| 2015-06-30 | $22.57M 10-K · filed 2017-02-28 | $6.84M derived: sum of 2 quarters · filed 2017-02-28 | ||||||
| 2015-03-31 | -$15.73M 10-K · filed 2017-02-28 | |||||||
| 2014-12-31 | $54.27M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |